Lyra Medical

Company Overview

Snapshot

Founded in July 2011 by Iram Levit and Gil Levy, Lyra Medical operates with 1–10 employees. The company has secured funding across one round from one investor. In January 2016, Lyra Medical secured additional funding to advance its clinical and regulatory efforts for its pelvic organ prolapse treatment technology.

Business overview

Lyra Medical is a Health Tech & Life Sciences company focused on developing a safe, long-term solution for pelvic floor repair. The company's core technology, Self-Retaining Support (SRS), is utilized in its flagship Lyra system designed for anterior vaginal wall, apex, and uterine prolapse. This support platform also has potential applications in other pelvic organ disorders, including rectocele and urinary incontinence, as well as broader clinical areas such as hernias. Lyra Medical serves the healthcare market, specifically targeting patients and providers in gynecology, urology, and women's health.

Strategic signal

In January 2016, Lyra Medical secured additional funding to fuel its clinical and regulatory affairs efforts for its pelvic organ prolapse treatment technology. This event signals investor confidence in the company's innovative approach to women's health and its progress towards market entry, indicating a focus on advancing product development and securing necessary approvals for commercialization.

Company Intelligence Q&A

When was Lyra Medical founded and by whom?

Lyra Medical was founded in July 2011 by co-founders Iram Levit and Gil Levy.

What is Lyra Medical's primary focus?

Lyra Medical focuses on developing a long-term solution for pelvic floor repair, specifically addressing pelvic organ prolapse in women using its Self-Retaining Support technology.

What is the status of Lyra Medical's regulatory approvals?

Lyra Medical is currently obtaining EU and Israeli regulatory approval (CE mark and AMAR) for its product.

Has Lyra Medical conducted clinical studies for its technology?

Yes, Lyra Medical has completed two clinical studies involving a total of 70 patients, which have shown excellent results.

What is Lyra Medical's intellectual property status?

Lyra Medical holds a robust IP portfolio, including approved US and EU patents and pending applications in other regions.